Summary
Terfenadine, a nonsedating H1-selective antihistamine, is widely used in many countries. We report pharmacokinetic results in a patient who developed a prolonged QT-interval in ECG and symptomatic torsades de pointes ventricular tachycardia as a consequence of the interaction of itraconazole and terfenadine. Both drugs were taken in the recommended doses: terfenadine 60 mg b.d. and itraconazole 100 mg b.d.
Terfenadine metabolism was delayed by itraconazole, leading to an increased level of unmetabolised terfenadine. Seven weeks after the cessation of itraconazole treatment, terfenadine was rapidly metabolized to its active metabolite and did not prolong the QT-interval when given as a single provocation dose (120 mg).
The findings suggest that intraconazole in therapeutic doses inhibits terfenadine metabolism. It is also possible that unmetabolised terfenadine alone, without an increased level of its active metabolite, may cause torsades de pointes. The concomitant use of terfenadine and itraconazole (and ketoconazole) should be avoided.
This is a preview of subscription content, log in via an institution to check access.
References
Davies AJ, Harindra V, McEvan A, Ghose RR (1989) Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 298: 325
MacConnell TJ, Stanners AJ (1991) Torsades de pointes complicating treatment with terfenadine. BMJ 302: 1469
Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264: 2788–2790
Zimmerman M, Duruz H, Broccard O, Levy D, Lacatis D, Bloch A (1992) Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 13: 1002–1003
Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P (1993) Torsades de pointes ventricular tachycardia caused by itraconazole-terfenadine interaction. BMJ 306: 186
Bazett HC (1918) An analysis of the relations of electrocardiograms. Heart 7: 353–370
Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark MC, Lazzara R (1988) The long QT-syndromes: a critical reviw, new clinical observations and a unifying hypothesis. Progr Cardiovasc Dis 31: 115–172
Kallio J (1990) The effect of urine pH on debrisoquine phenotyping: application of an HPLC-method. Int J Clin Pharmacol Ther Toxicol 28: 223–226
Mathews DR, McNutt B, Okerholm R, Flicker M, McBride G (1991) Torsades de pointes occurring in association with terfenadine use. JAMA 266: 2375–2376
Simons FER, Kesselman MS, Giddins NG, Pelech AN, Simons KJ (1988) Astemizole-induced torsade de pointes. Lancet II: 624
Clark A, Love H (1991) Astemizole-induced ventricular arrhythmias: an unexpected cause of convulsions. Int J Cardiol 33: 165–167
Hoppu K, Tikanoja T, Tapanainen P, Remes M, Saarenpää-Heikkilä O, Kouvalainen K (1991) Accidental astemizole overdose in young children. Lancet 338: 538–540
Eller MG, Okerholm RA (1991) Pharmacokinetic interaction between terfenadine and ketoconazole. Clin Pharmacol Ther 49: 130
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pohjola-Sintonen, S., Viitasalo, M., Toivonen, L. et al. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 45, 191–193 (1993). https://doi.org/10.1007/BF00315505
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315505